Publications by authors named "Filip Dubovsky"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

230,141

Total Likes

4,707

Extended Reach

1,125,949

Social Features

254
S
Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M nanoparticle vaccine induces neutralizing responses in nonhuman primates.
Nita Patel, Asma Rehman, Jessica F Trost, Rhonda Flores, Zach Longacre, Filip Dubovsky

Nat Commun· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
X
XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants.
Nita Patel, Jessica F Trost, Mimi Guebre-Xabier, Haixia Zhou, Jim Norton, Filip Dubovsky

Sci Rep· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 Severe Acute Respiratory Syndrome Coronavirus 2 Primary Vaccination.
Louis Fries, Neil Formica, Raburn M Mallory, Haixia Zhou, Joyce S Plested, Filip Dubovsky

J Infect Dis· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Filip Dubovsky

Vaccine· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents: A Randomized Clinical Trial.
Germán Áñez, Lisa M Dunkle, Cynthia L Gay, Karen L Kotloff, Jeffrey M Adelglass, Filip Dubovsky

JAMA Netw Open· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373.
Katia Alves, Joyce S Plested, Shirley Galbiati, Gordon Chau, Shane Cloney-Clark, Filip Dubovsky

N Engl J Med· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A prefusion-stabilized RSV F subunit vaccine elicits B cell responses with greater breadth and potency than a postfusion F vaccine.
Lauren A Chang, Emily Phung, Michelle C Crank, Kaitlyn M Morabito, Tonya Villafana, Filip Dubovsky

Sci Transl Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Immunogenicity and Efficacy of NVX-CoV2373 in Adolescents in PREVENT-19: A Randomized, Phase 3 Trial.
Germán Áñez, Lisa M Dunkle, Cynthia L Gay, Karen L Kotloff, Jeffrey M Adelglass, Filip Dubovsky

medRxiv· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial.
Seth Toback, Eva Galiza, Catherine Cosgrove, James Galloway, Anna L Goodman, Filip Dubovsky

Lancet Respir Med· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial.
Neil Formica, Raburn Mallory, Gary Albert, Michelle Robinson, Joyce S Plested, Filip Dubovsky

PLoS Med· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
Bruno François, Hasan S Jafri, Jean Chastre, Miguel Sánchez-García, Philippe Eggimann, Filip Dubovsky

Lancet Infect Dis· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine.
Paul T Heath, Eva P Galiza, David N Baxter, Marta Boffito, Duncan Browne, Filip Dubovsky

N Engl J Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
Vivek Shinde, Sutika Bhikha, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Filip Dubovsky

N Engl J Med· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines.
Xiaoying Shen, Haili Tang, Charlene McDanal, Kshitij Wagh, Will Fischer, Filip Dubovsky

bioRxiv· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants.
M Pamela Griffin, Yuan Yuan, Therese Takas, Joseph B Domachowske, Shabir A Madhi, Filip Dubovsky

N Engl J Med· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A study to evaluate the immunogenicity and shedding of live attenuated influenza vaccine strains in children 24-<48 months of age.
Raburn M Mallory, Andrew Nyborg, Rubana N Kalyani, Yuan Yuan, Stan L Block, Filip Dubovsky

Vaccine· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
S Omar Ali, Therese Takas, Andrew Nyborg, Kathryn Shoemaker, Nicole L Kallewaard, Filip Dubovsky

Antimicrob Agents Chemother· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants.
Joseph B Domachowske, Anis A Khan, Mark T Esser, Kathryn Jensen, Therese Takas, Filip Dubovsky

Pediatr Infect Dis J· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The safety and efficacy of quadrivalent live attenuated influenza vaccine in Japanese children aged 2-18 years: Results of two phase 3 studies.
Raburn M Mallory, Jing Yu, Sachiko Kameo, Michio Tanaka, Ki Rito, Filip Dubovsky

Influenza Other Respir Viruses· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An Adjuvanted, Postfusion F Protein-Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults.
Judith Falloon, Jing Yu, Mark T Esser, Tonya Villafana, Li Yu, Filip Dubovsky

J Infect Dis· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers.
Raburn M Mallory, S Omar Ali, Therese Takas, Martin Kankam, Filip Dubovsky

Biologicals· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses.
Judith Falloon, H Keipp Talbot, Craig Curtis, John Ervin, Diane Krieger, Filip Dubovsky

Clin Vaccine Immunol· September 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
M Pamela Griffin, Anis A Khan, Mark T Esser, Kathryn Jensen, Therese Takas, Filip Dubovsky

Antimicrob Agents Chemother· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Judith Falloon, Fei Ji, Craig Curtis, Stephan Bart, Eric Sheldon, Filip Dubovsky

Vaccine· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis